Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Temsirolimus | MTOR | MTOR | 0.1192 | 1.7003 | 10.0307 | -0.9332 | -0.8176 | -0.6679 | -1.0000 | -1.0000 | -0.9967 | 0.2520 | 0.4363 | 1.0813 | 0.3951 | 0.4933 | 0.6311 | 6.4751 | 18.8586 | 43.0334 | |
5-FU | TYMS | TYMS | 43.5628 | 98.8715 | 100.0000 | -0.6126 | -0.4736 | -0.0711 | -0.8532 | -0.6532 | -0.1200 | 0.5225 | 0.5967 | 0.7832 | 0.3295 | 0.4853 | 0.6100 | 100.0000 | 100.0000 | 100.0000 | |
Etoposide | TOP2 | TOP | 1.1610 | 2.9708 | 7.6285 | -0.6938 | -0.4841 | -0.2079 | -0.7406 | -0.5842 | -0.4690 | 0.5531 | 0.8108 | 1.2247 | 0.3770 | 0.4769 | 0.5711 | 4.4274 | 7.6731 | 19.6965 | |
GSK923295 | CENPE | Kinesin | 0.0392 | 0.0651 | 0.2250 | -0.5702 | -0.2653 | -0.0001 | -0.5044 | -0.2084 | 0.0089 | 1.0722 | 2.1595 | 3.4297 | 0.3588 | 0.4764 | 0.6241 | 0.0452 | 0.0615 | 1.0057 | |
Imatinib | ABL/KIT/PDGFR | nRTK | 18.5481 | 21.7914 | 25.5570 | -0.9852 | -0.9632 | -0.8948 | -0.9969 | -0.9814 | -0.8936 | 2.2328 | 2.7060 | 3.3541 | 0.3997 | 0.4467 | 0.4851 | 27.9144 | 31.9309 | 36.9254 | |
Everolimus | MTOR | MTOR | 0.0432 | 0.6717 | 4.3873 | -0.8294 | -0.6714 | -0.2303 | -1.0000 | -1.0000 | -0.6838 | 0.2890 | 0.4230 | 0.7677 | 0.3295 | 0.4415 | 0.5925 | 1.5205 | 9.7227 | 26.2255 | |
TCS 2312 | CHK1 | CHK | 0.3474 | 0.6156 | 0.9604 | -0.8358 | -0.6163 | -0.3941 | -0.8432 | -0.6104 | -0.3951 | 1.4081 | 2.0751 | 2.9131 | 0.3572 | 0.4368 | 0.5565 | 0.6031 | 1.0589 | 1.5099 | |
Sunitinib | PDGFR/VEGFR/KIT/FLT3 | RTK | 4.8478 | 6.2817 | 9.9436 | -0.9902 | -0.9623 | -0.8818 | -0.9966 | -0.9683 | -0.8864 | 1.4527 | 2.4005 | 3.5359 | 0.3679 | 0.4354 | 0.4695 | 8.0047 | 9.6271 | 12.8243 | |
Pevonedistat | NAE1 | NAE1 | 0.1439 | 0.3445 | 1.2615 | -0.3074 | -0.0880 | 0.0407 | -0.4612 | -0.1540 | 0.0480 | 0.6476 | 0.9529 | 1.4328 | 0.3433 | 0.4344 | 0.5442 | 0.1672 | 0.7014 | 1.4696 | |
IKK16 | IKK | NFKB | 1.8767 | 3.1049 | 3.8519 | -0.9668 | -0.9445 | -0.8619 | -0.9890 | -0.9578 | -0.8641 | 2.2018 | 3.4729 | 4.3592 | 0.3739 | 0.4332 | 0.4763 | 3.1521 | 4.0389 | 4.8853 | |
Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.2491 | 0.7096 | 1.5478 | -0.9565 | -0.8762 | -0.7290 | -1.0000 | -1.0000 | -0.9202 | 0.6212 | 0.8572 | 1.4388 | 0.3615 | 0.4228 | 0.5481 | 1.3258 | 2.5025 | 5.3389 | |
Sirolimus | MTOR | MTOR | 0.0785 | 2.7199 | 100.0000 | -0.0907 | 0.1172 | 0.3521 | -0.3854 | 0.0690 | 0.4042 | 0.2746 | 0.5743 | 1.0909 | 0.2471 | 0.4095 | 0.5054 | 0.0261 | 0.5698 | 12.7823 | |
CGC-11047 | Polyamine analogue | N/A | 43.1451 | 85.4630 | 100.0000 | -0.8722 | -0.7234 | -0.2437 | -1.0000 | -0.9172 | -0.4365 | 0.4134 | 0.5735 | 1.1488 | 0.3172 | 0.3971 | 0.4905 | 94.6485 | 100.0000 | 100.0000 | |
Bosutinib | Src | nRTK | 1.2187 | 1.7497 | 4.1420 | -0.6727 | -0.4219 | -0.1512 | -0.7662 | -0.4684 | -0.1288 | 0.9612 | 1.6575 | 1.9534 | 0.3079 | 0.3819 | 0.4639 | 1.7722 | 2.5602 | 5.3523 | |
Cisplatin | DNA cross-linker | DNA cross-linker | 4.4823 | 11.6380 | 25.2438 | -0.8850 | -0.6449 | -0.2565 | -0.9047 | -0.5931 | -0.2921 | 1.0217 | 1.3698 | 2.2177 | 0.2715 | 0.3752 | 0.4391 | 8.7984 | 21.1543 | 38.4325 | |
Carboplatin | DNA cross-linker | DNA cross-linker | 30.4522 | 52.4276 | 91.0569 | -0.9081 | -0.7672 | -0.5844 | -0.9460 | -0.8644 | -0.7390 | 1.2433 | 1.6402 | 2.1619 | 0.2714 | 0.3706 | 0.4859 | 52.1319 | 91.7409 | 100.0000 | |
XRP44X | ELK3 | MAPK | 0.7816 | 1.1482 | 1.8976 | -0.2021 | 0.0602 | 0.2789 | -0.1369 | 0.0575 | 0.2934 | 1.8769 | 3.3942 | 4.9998 | 0.2905 | 0.3686 | 0.4637 | 0.6561 | 1.0109 | 1.3678 | |
Mebendazole | N/A | N/A | 0.2591 | 0.5241 | 2.5192 | -0.2079 | 0.0053 | 0.2103 | -0.2699 | -0.1133 | 0.2272 | 0.7947 | 1.2360 | 1.9961 | 0.2868 | 0.3432 | 0.4692 | 0.3151 | 0.3915 | 2.6571 | |
Olomoucine II | CDK1 | CDK | 3.7444 | 6.0358 | 7.3956 | -0.7023 | -0.3927 | -0.1441 | -0.7230 | -0.4357 | -0.1137 | 1.4260 | 2.7083 | 4.7257 | 0.2563 | 0.3202 | 0.3981 | 5.9885 | 7.0813 | 8.6384 | |
Triciribine | AKT | AKT | 0.1497 | 1.0069 | 10.2321 | -0.2208 | 0.0730 | 0.3595 | -0.6783 | -0.3270 | 0.0049 | 0.3693 | 0.5173 | 0.9769 | 0.1961 | 0.3180 | 0.4712 | 0.2958 | 1.3169 | 18.2553 | |
5-DFUR | TYMS | TYMS | 68.5295 | 100.0000 | 100.0000 | -0.1871 | -0.0208 | 0.0399 | -0.5625 | -0.3158 | -0.1425 | 0.3943 | 0.5084 | 0.6195 | 0.2584 | 0.3100 | 0.3856 | 100.0000 | 100.0000 | 100.0000 | |
Tozasertib | AURK/FLT3/ABL/JAK2 | AURK | 0.9523 | 4.3787 | 11.8540 | -0.5661 | -0.3376 | -0.0359 | -1.0000 | -1.0000 | -0.4350 | 0.4858 | 0.8218 | 1.3502 | 0.1794 | 0.3014 | 0.3656 | 4.7346 | 16.5294 | 34.8041 | |
GSK1838705A | IGF1R | RTK | 4.0665 | 10.9435 | 23.1329 | -0.6969 | -0.3849 | -0.1067 | -0.7773 | -0.4275 | -0.2150 | 1.5275 | 2.6721 | 3.2208 | 0.2264 | 0.2964 | 0.4149 | 2.6121 | 7.6760 | 17.5013 | |
GSK1070916 | AURK | AURK | 0.6046 | 3.0981 | 6.6549 | -0.8474 | -0.6391 | -0.3610 | -1.0000 | -1.0000 | -0.9999 | 0.6499 | 0.9902 | 1.5949 | 0.2113 | 0.2924 | 0.4314 | 3.5405 | 8.2453 | 15.6107 | |
Sigma A6730 | AKT | AKT | 2.0327 | 6.5660 | 11.2198 | -0.9178 | -0.8320 | -0.6777 | -1.0000 | -1.0000 | -0.9546 | 0.9310 | 1.3794 | 2.0044 | 0.2439 | 0.2875 | 0.4042 | 6.3004 | 13.6236 | 19.0461 |